Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.46 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.45 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19610380 | 0.92 | TEAD1 (0.43) | PARP15PARP10PARP2TEAD1TEAD3 | |
| SCHEMBL20744509 | 0.90 | F2 (0.44) | TEAD1TEAD3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20744502 | 0.86 | PARP15 (0.43) | PARP15PARP10PARP2 | |
| SCHEMBL5207764 | 0.86 | POLB (0.56) | PARP15PARP10PARP2 | |
| SCHEMBL19615541 | 0.84 | PARP15 (0.42) | PARP15PARP10PARP2 | |
| SCHEMBL12813444 | 0.84 | GRIN2D (0.53) | PARP15PARP10PARP2GRIN2DGRIN3B | |
| SCHEMBL796332 | 0.84 | GRIN2D (0.55) | PARP15PARP10PARP2TEAD1TEAD3 | |
| SCHEMBL19610302 | 0.83 | MAPT (0.48) | TEAD1TEAD3 | |
| SCHEMBL214491 | 0.83 | PARP15 (0.51) | PARP15PARP10PARP2GRIN2DGRIN3B | |
| SCHEMBL13519209 | 0.83 | MEN1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668877-B1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-05-01 | — | — | EP | disclosed |
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-20 | — | — | US | disclosed |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-03-30 | — | — | US | disclosed |
| EP-3458460-B1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-12-09 | — | — | EP | disclosed |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-17 | — | — | US | disclosed |
| EP-3668877-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2020-06-24 | — | — | EP | disclosed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-05-23 | — | — | US | disclosed |
| EP-3458460-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2019-03-27 | — | — | EP | disclosed |
| WO-2019034774-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA (IEO) S.R.L. (IT) | 2019-02-21 | — | — | WO | disclosed |
| WO-2017198780-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-11-23 | — | — | WO | disclosed |
| EP-3246330-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | KDM1B, KDM1A, INMT | PARP15 609/4885PARP10 650/4885PARP2 519/4885 |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, INMT | PARP15 609/4885PARP10 650/4885PARP2 519/4885 |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, DOT1L | PARP15 839/4885PARP10 798/4885PARP2 848/4885 |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | DOT1L, KDM1B, KDM1A | PARP15 612/4885PARP10 534/4885PARP2 658/4885 |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | KDM1B, KDM1A, DOT1L | PARP15 839/4885PARP10 798/4885PARP2 848/4885 |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | DOT1L, KDM1B, KDM1A | PARP15 612/4885PARP10 534/4885PARP2 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.